Increased cell proliferation, tumor volume and weight with the SLC3A2-NRG1 fusion were significantly eliminated when a SLC3A2-NRG1Δ EGF truncated form was used in the same cancer cells (Figure 2C, 2D, and Supplemental Figure S6B). This evidence concerns the gene SLC3A2 and cancer.